EU External Trade - Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes, Immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale

Extra-EU sourcing of Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes, Immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale is highly concentrated. 🇨🇭 Switzerland captures 36.7% of imports (€2.3B), followed by 🇺🇸 United States (34.1%). With an HHI of 2718, this Concentrated market exposes the EU to supply dependency risks.

European exports of Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes, Immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale are concentrated on a few markets. 🇨🇭 Switzerland accounts for 47.9% (€793.5M), ahead of 🇺🇸 United States (29.1%). The top three destinations are 🇨🇭 Switzerland, 🇺🇸 United States, 🇬🇧 United Kingdom.

Within the EU, the leading importers of Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes, Immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale are 🇩🇪 Germany, 🇮🇪 Ireland, 🇮🇹 Italy. 🇩🇪 Germany accounts for 35.3% of EU imports.

In 2025, imports were stable (2.7%) and exports surging (78.7%) compared to the previous year.